Modified Nucleosides
4'-Thioadenosine
Quick view. We supply 4'-Thioadenosine as a specialty product for nucleic acid chemistry and oligonucleotide research workflows. CAS 2500-80-3. Catalog target purity: Specification on request.
Structure and identity
The structure drawing for this item is being finalized. Use the CAS number and machine-readable identifiers below to confirm the requested protecting groups, stereochemistry, salt or counterion and hydration state before ordering.
CAS, molecular formula, SMILES or InChI data are shown below when available.
We withhold a drawing when a related compound, alternate salt or incompletely specified stereoisomer could be mistaken for the requested material.
Agreed identity and purity criteria are documented in the quotation, specification and lot-specific data package.
Product profile
4'-Thioadenosine is classified as nucleoside or protected nucleoside intermediate (Formula C10H13N5O3S; molecular weight 283.31).
4'-Thioadenosine can serve as a starting material, protected intermediate or analytical comparator in nucleoside and nucleotide route development.
For 4'-Thioadenosine, confirm the current specification, storage conditions and downstream-method compatibility before routine use.
Names and search terms
Confirmed or normalized name variants
- Nsc 82219
- Adenosine, 4'-thio-
- (2R,3R,4S,5R)-2-(6-Amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrothiophene-3,4-diol
Useful catalog search terms
- CAS 2500-80-3
- Nucleoside or protected nucleoside intermediate
- Modified Nucleosides
Physicochemical data
| Melting point | 125.4-126.3 °C |
|---|---|
| Boiling point | 657.8±65.0 °C(Predicted) |
| Density | 2.08±0.1 g/cm3(Predicted) |
| pKa | 13.05±0.70(Predicted) |
Release documentation
The current specification defines the analytical method and acceptance criteria; the released lot result is reported on the CoA.
Additional HPLC, MS or NMR documentation can be agreed during technical review where available.
Additional application examples
- Typical work includes protection/deprotection studies, phosphorylation or phosphitylation route scouting and impurity identification.
- The material can support medicinal-chemistry analog preparation and process-development feasibility studies.
Related products
(S)-cEt-rA
Modified Nucleosides · CAS: 1197033-34-3
BX-OP-0069S-Adenosylmethionine (SAM)
Modified Nucleosides · CAS: 485-80-3
BX-MN-0185(R-/S-) 5-Carbamoylhydroxy methyluridine
Modified Nucleosides · CAS: N/A
BX-MN-0186(R-/S-)5-(1-Hydroxy)(methoxycarbonyl)methyl uridine
Modified Nucleosides · CAS: N/A
BX-MN-0187(R-/S-)5-Carboxyhydroxymethyl uridine
Modified Nucleosides · CAS: N/A
BX-MN-0719(R)-N-(2,3-dihydro-1H-indenyl)adenosine
Modified Nucleosides · CAS: 96392-15-3
Frequently asked questions
Can the package size for 4'-Thioadenosine be customized?
Yes. Share the initial quantity, expected future scale, delivery timeline and packaging preference for review.
What information should be included in a quote request?
Quote catalog number BX-MN-0420 and CAS 2500-80-3, the intended research workflow, required quantity and any additional HPLC, MS or NMR documentation needed.
Product-relevant literature
The publications below discuss 4'-Thioadenosine or the named structural feature represented by this product.
- Exploring C2 and N 6 Substituent Effects on Truncated 4'-Thioadenosine Derivatives as Dual A 2A and A 3 Adenosine Receptor Ligands. (2025)
- Design, Synthesis, and Biological Evaluation of C2-(N-Substituted Amino) Truncated 4'-Thioadenosine Derivatives as A<sub>2A</sub>AR and A<sub>3</sub>AR Dual Ligands. (2025)
- Steric influence of 4'-position substituents and C2-Hexynyl group on A<sub>3</sub>AR antagonism in truncated 4'-Thioadenosine derivatives. (2025)
- Structure-activity relationship analysis of 5'-substituted C2-hexynyl-4'-thioadenosine analogs as dual A<sub>2A</sub>/A<sub>3</sub> adenosine receptor agonists with tunable selectivity and anti-inflammatory activity. (2026)
- Stereochemical influence of 4'-methyl substitutions on truncated 4'-thioadenosine derivatives: Impact on A<sub>3</sub> adenosine receptor binding and antagonism. (2024)